Pacira BioSciences, Inc.(PCRX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Pacira BioSciences, Inc. (PCRX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PCRX at 51.5/100 on a 32-signal composite quality model, placing it at rank #1,521 of 2,960 stocks — the bottom half of the AI-ranked universe. PCRX scores in the top quartile across earnings quality (97.4), free cash flow (77.7). Areas of concern include institutional flow (28.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 19.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Pacira BioSciences, Inc. reports quarterly revenue of $192.4M, net income of $4.7M, an operating margin of 2.2%. Top institutional holders of PCRX by reported 13-F value include BlackRock, LINDEN ADVISORS, Context Capital Management, based on the most recent SEC filings. PCRX trades on the Nasdaq exchange and files with the SEC under CIK 1396814. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PCRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Pacira BioSciences, Inc. directly from SEC EDGAR.